Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and Aggressiveness.

Autor: Lygirou V; Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527 Athens, Greece., Fasoulakis K; Department of Urology, Ippokrateio General Hospital of Athens, 114 Vasilissis Sofias Avenue, 11527 Athens, Greece.; Laikon Hospital, 1st Urology Department, Medical School, National and Kapodistrian University of Athens, 17 Agiou Thoma Street, 11527 Athens, Greece., Stroggilos R; Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527 Athens, Greece., Makridakis M; Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527 Athens, Greece., Latosinska A; Mosaiques Diagnostics GmbH, 30659 Hannover, Germany., Frantzi M; Mosaiques Diagnostics GmbH, 30659 Hannover, Germany., Katafigiotis I; Laikon Hospital, 1st Urology Department, Medical School, National and Kapodistrian University of Athens, 17 Agiou Thoma Street, 11527 Athens, Greece., Alamanis C; Laikon Hospital, 1st Urology Department, Medical School, National and Kapodistrian University of Athens, 17 Agiou Thoma Street, 11527 Athens, Greece., Stravodimos KG; Laikon Hospital, 1st Urology Department, Medical School, National and Kapodistrian University of Athens, 17 Agiou Thoma Street, 11527 Athens, Greece., Constantinides CA; Laikon Hospital, 1st Urology Department, Medical School, National and Kapodistrian University of Athens, 17 Agiou Thoma Street, 11527 Athens, Greece., Vlahou A; Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527 Athens, Greece., Zoidakis J; Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527 Athens, Greece.; Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 15701 Athens, Greece.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2022 Aug 02; Vol. 14 (15). Date of Electronic Publication: 2022 Aug 02.
DOI: 10.3390/cancers14153765
Abstrakt: Prostate cancer (PCa) is the second most common cancer in men. Diagnosis and risk assessment are widely based on serum Prostate Specific Antigen (PSA) and biopsy, which might not represent the exact degree of PCa risk. Towards the discovery of biomarkers for better patient stratification, we performed proteomic analysis of Formalin Fixed Paraffin Embedded (FFPE) prostate tissue specimens using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Comparative analysis of 86 PCa samples among grade groups 1-5 identified 301 significantly altered proteins. Additional analysis based on biochemical recurrence (BCR; BCR+ n = 14, BCR- n = 51) revealed 197 significantly altered proteins that indicate disease persistence. Filtering the overlapping proteins of these analyses, seven proteins ( NPM1 , UQCRH , HSPA9 , MRPL3 , VCAN , SERBP1 , HSPE1 ) had increased expression in advanced grades and in BCR+/BCR- and may play a critical role in PCa aggressiveness. Notably, all seven proteins were significantly associated with progression in Prostate Cancer Transcriptome Atles (PCTA) and NPM1NPM1 , UQCRH , and VCAN were further validated in The Cancer Genome Atlas (TCGA), where they were upregulated in BCR+/BCR-. UQCRH levels were also associated with poorer 5-year survival. Our study provides valuable insights into the key regulators of PCa progression and aggressiveness. The seven selected proteins could be used for the development of risk assessment tools.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje